Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics, Inc. Chief Medical Officer Douglas Kerr reported an automatic sale of 1,564 shares of common stock. The shares were sold on May 13, 2026 at a weighted average price of $18.36 per share in multiple trades between $18.20 and $18.41.
The filing explains that these shares were automatically sold to satisfy tax withholding obligations related to the vesting of restricted stock units granted on February 12, 2026, under a restricted stock unit agreement described as a binding contract consistent with the affirmative defense under Rule 10b5-1. After this transaction, Kerr directly holds 170,042 shares of Dyne Therapeutics common stock, including 148,313 unvested restricted stock units.
Dyne Therapeutics, Inc. Chief Financial Officer Erick Lucera reported an automatic sale of 1,448 shares of common stock. The shares were sold in the open market at a weighted average price of $18.36 per share, within a range of $18.20 to $18.41.
According to the disclosure, this sale was automatically executed to cover tax withholding obligations tied to the vesting of restricted stock units granted on February 12, 2026, under a restricted stock unit agreement characterized as a binding contract consistent with the affirmative defense under Rule 10b5-1. Following the transaction, Lucera holds 123,925 shares directly, including 110,513 unvested restricted stock units.
Dyne Therapeutics CEO John Cox reported an automatic tax-related sale of 3,311 shares of common stock. The shares were sold on May 13, 2026 at a weighted average price of $18.36 per share to satisfy tax withholding obligations tied to the vesting of restricted stock units granted on February 12, 2026.
The sale was executed under a restricted stock unit agreement described as a binding contract consistent with the Rule 10b5-1 affirmative defense, meaning it was not a discretionary trade. After this transaction, Cox directly holds 370,834 shares, including 268,645 unvested RSUs, and also reports indirect holdings through trusts for the benefit of a child.
DYN filer submitted a Form 144 notice relating to proposed sales of Common Stock consisting of 11,250 Restricted Stock Units and disclosing a prior disposition of 2,732 shares on 03/05/2026. The filing lists 165,313,769 shares outstanding as of 05/13/2026.
DYN filed a Rule 144 notice reporting a recent restricted‑stock issuance and a resale by an affiliate. The filing lists 4,062 Restricted Stock Units granted on 05/12/2026 and a reported resale of 5,727 shares on 04/01/2026 by Erick Lucera. The excerpt shows 165,313,796 shares outstanding as of 05/13/2026.
Dyne Therapeutics reported first quarter 2026 results and highlighted progress in its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs. Cash, cash equivalents and marketable securities were $972.2 million as of March 31, 2026, which the company expects will fund operations into the first quarter of 2028.
For the quarter ended March 31, 2026, research and development expenses were $100.9 million versus $106.4 million a year earlier, while general and administrative expenses rose to $24.4 million from $15.9 million, mainly to prepare for a potential z-rostudirsen launch. Net loss was $120.9 million, or $0.73 per share, compared with a net loss of $115.4 million, or $1.05 per share, in the prior-year period.
Clinically, Dyne completed a positive pre-BLA meeting with the FDA for z-rostudirsen in exon 51 DMD, remains on track to submit a BLA for U.S. Accelerated Approval in Q2 2026, and is planning a potential U.S. launch in Q1 2027. The company also reached its target of 60 participants in the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1, initiated the Phase 3 HARMONIA trial, and is planning data from the ACHIEVE cohort in Q1 2027 to support a potential BLA submission in early Q3 2027.
Dyne Therapeutics reported a net loss of $120.9 million for the quarter ended March 31, 2026, slightly higher than the $115.4 million loss a year earlier, as it continues to advance multiple neuromuscular programs.
Research and development expenses were $100.9 million, reflecting manufacturing and clinical work on z-rostudirsen for Duchenne muscular dystrophy and z-basivarsen for myotonic dystrophy type 1, plus preclinical efforts in FSHD and Pompe. General and administrative costs rose to $24.4 million as Dyne scales commercial and corporate infrastructure. The company ended the quarter with $972.2 million in cash, cash equivalents and marketable securities and a term loan balance of $150.0 million, and believes this liquidity will fund operations, debt service and capital needs into the first quarter of 2028 while it targets potential first product launches beginning in 2027.
Dyne Therapeutics, Inc. reported that investment entities associated with director Jason P. Rhodes sold a total of 106,723 shares of its common stock in open-market transactions. The sales occurred on May 4–6, 2026 at weighted average prices around $18.00–$18.18 per share under a Rule 10b5-1 trading plan.
The trades were executed by Atlas Venture-managed funds and related partnerships that hold Dyne shares indirectly for investors. After these transactions, the entities still hold multi-million-share positions in Dyne across several funds, while Rhodes disclaims beneficial ownership beyond any pecuniary interest.